

## Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Hannah A. Blair<sup>1</sup>

Published online: 24 January 2018  
© Springer International Publishing AG, part of Springer Nature 2018

**Correction to: Drugs (2017) 77:2013–2024**  
<https://doi.org/10.1007/s40265-017-0837-7>

The author has alerted us to the following error in Sect. 4.2.2.1, and the following correction should be noted:

Page 2019, Sect. 4.2.2.1, paragraph 1, lines 6–10: the following sentence, which previously read:

“After a median follow-up of 24.5 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly ( $p < 0.0001$ ) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31–0.53)”.

should read:

“After a median follow-up of 25.4 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly ( $p < 0.0001$ ) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31–0.53)”.

---

The original article can be found online at <https://doi.org/10.1007/s40265-017-0837-7>.

---

✉ Hannah A. Blair  
demail@springer.com

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand